The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular and vascular penile ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback